These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 38500772)

  • 1. Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells.
    Pelon M; Krzeminski P; Tracz-Gaszewska Z; Misiewicz-Krzeminska I
    Front Pharmacol; 2024; 15():1351565. PubMed ID: 38500772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib- and carfilzomib-resistant myeloma cells show increased activity of all three arms of the unfolded protein response.
    Kubicki T; Bednarek K; Kostrzewska-Poczekaj M; Luczak M; Lewandowski K; Gil L; Jarmuz-Szymczak M; Dytfeld D
    Am J Cancer Res; 2022; 12(7):3280-3293. PubMed ID: 35968359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
    Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
    Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
    Meister S; Schubert U; Neubert K; Herrmann K; Burger R; Gramatzki M; Hahn S; Schreiber S; Wilhelm S; Herrmann M; Jäck HM; Voll RE
    Cancer Res; 2007 Feb; 67(4):1783-92. PubMed ID: 17308121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The proteasome and proteasome inhibitors in multiple myeloma.
    Gandolfi S; Laubach JP; Hideshima T; Chauhan D; Anderson KC; Richardson PG
    Cancer Metastasis Rev; 2017 Dec; 36(4):561-584. PubMed ID: 29196868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of P-Glycoprotein Does Not Increase the Efficacy of Proteasome Inhibitors in Multiple Myeloma Cells.
    Mynott RL; Wallington-Beddoe CT
    ACS Pharmacol Transl Sci; 2021 Apr; 4(2):713-729. PubMed ID: 33860196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Proteasome inhibitors in treatment of multiple myeloma].
    Kubiczková L; Matějíková J; Sedlaříková L; Kryukov F; Hájek R; Sevčíková S
    Klin Onkol; 2013; 26(1):11-8. PubMed ID: 23528167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance.
    Kraus M; Bader J; Overkleeft H; Driessen C
    Blood Cancer J; 2013 Mar; 3(3):e103. PubMed ID: 23454896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.
    Ling SC; Lau EK; Al-Shabeeb A; Nikolic A; Catalano A; Iland H; Horvath N; Ho PJ; Harrison S; Fleming S; Joshua DE; Allen JD
    Haematologica; 2012 Jan; 97(1):64-72. PubMed ID: 21993678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition.
    Bennett MK; Li M; Tea MN; Pitman MR; Toubia J; Wang PP; Anderson D; Creek DJ; Orlowski RZ; Gliddon BL; Powell JA; Wallington-Beddoe CT; Pitson SM
    Neoplasia; 2022 Jan; 24(1):1-11. PubMed ID: 34826777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells.
    Baranowska K; Misund K; Starheim KK; Holien T; Johansson I; Darvekar S; Buene G; Waage A; Bjørkøy G; Sundan A
    Oncotarget; 2016 Oct; 7(43):70845-70856. PubMed ID: 27683126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax.
    Downey-Kopyscinski SL; Srinivasa S; Kisselev AF
    Sci Rep; 2022 Jul; 12(1):12788. PubMed ID: 35896610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
    Kuhn DJ; Chen Q; Voorhees PM; Strader JS; Shenk KD; Sun CM; Demo SD; Bennett MK; van Leeuwen FW; Chanan-Khan AA; Orlowski RZ
    Blood; 2007 Nov; 110(9):3281-90. PubMed ID: 17591945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors.
    Zangari M; Berno T; Yang Y; Zeng M; Xu H; Pappas L; Tricot G; Kamalakar A; Yoon D; Suva LJ
    Bone; 2014 Apr; 61():39-43. PubMed ID: 24389365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural Agents as Novel Potential Source of Proteasome Inhibitors with Anti-Tumor Activity: Focus on Multiple Myeloma.
    Ambrosio FA; Costa G; Gallo Cantafio ME; Torcasio R; Trapasso F; Alcaro S; Viglietto G; Amodio N
    Molecules; 2023 Feb; 28(3):. PubMed ID: 36771100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-depth proteomic analysis of proteasome inhibitors bortezomib, carfilzomib and MG132 reveals that mortality factor 4-like 1 (MORF4L1) protein ubiquitylation is negatively impacted.
    Porras-Yakushi TR; Reitsma JM; Sweredoski MJ; Deshaies RJ; Hess S
    J Proteomics; 2021 Jun; 241():104197. PubMed ID: 33848640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma.
    Jayaweera SPE; Wanigasinghe Kanakanamge SP; Rajalingam D; Silva GN
    Front Oncol; 2021; 11():740796. PubMed ID: 34858819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs.
    Hasinoff BB; Patel D
    Cardiovasc Toxicol; 2018 Dec; 18(6):557-568. PubMed ID: 29951728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment.
    Chroma K; Skrott Z; Gursky J; Bacovsky J; Moudry P; Buchtova T; Mistrik M; Bartek J
    Cell Death Dis; 2022 Mar; 13(3):203. PubMed ID: 35246527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.